BER gene polymorphisms associated with key molecular events in bladder cancer
Keywords:
BER gene polymorphisms, bladder cancer, LOH, methylation, mutabilityAbstract
Summary. Aim: Base excision repair (BER) gene polymorphisms are known to play an independent role in predisposition to developing different cancers as well as to be associated with clinicopathological traits of the disease modifying its clinical outcomes. One of the underlying mechanisms is presumed to include interplay between BER gene polymorphisms and key mutational, epigenetic and chromosomal events in tumor tissues. The present study was aimed at elucidating potential gene-gene interaction and assessing their mutual effects in bladder cancer (BC). Materials and Methods: The earlier obtained data on genotyping patients with verified diagnosis of BC for OGG1 rs1052133 (Ser326Cys) and XRCC1 rs25487 (Arg399Gln) polymorphisms were used for this study. The tumor tissue samples from the same patients were analyzed for mutations, epigenetic variations and losses of heterozygosity in some key genes involved in divergent pathogenic pathways of BC. Results: It was shown that the OGG1 (326 codon) heterozygous genotype as well as the minor 326Cys allele can intensify a mutational response of the RAS locus in urothelial carcinomas in the total cohort of patients simultaneously decreasing the mutation rates in the PIK3CA locus in smokers. The XRCC1 (399 codon) heterozygous genotype as well as the minor 399Gln allele reduced the frequency of LOH in the PTEN and TNKS genes, but did not affect the mutational variability in any locus tested. Both polymorphisms influenced the methylation status, carriers of OGG1 326Ser/Cys or Ser/Cys+Cys/Cys genotypes demonstrating increased frequency of methylated RUNX3 and ISL1 genes whereas the similar effect of XRCC1 polymorphism concerning methylation of p16 and TIMP3 genes. When dividing the total cohort into groups based on the extent of tumor spread, the observed associations were characteristic of non-muscle invasive BC. Conclusion: The BER gene polymorphisms contributed to modification of key molecular events in urothelial carcinomas. Their mutual effects mainly manifested in non-muscle invasive BC. The underlying mechanisms as well as possible clinical outcomes need to be further explored to propose novel prognostic biomarkers for BC.
References
Okeanov AE, Moiseyev PI, Levin LF. Statistics of cancer diseases in the Republic of Belarus (2004–2013). Minsk: N.N. Alexandrov National Cancer Centre of Belarus, 2014. 382 p.
Janković S, Radosavljević V. Risk factors for bladder cancer. Tumori 2007; 93: 4–12.
Kakehi Y, Hirao Y, Kim WJ, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol 2010; 40: 57–64.
Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001; 291: 1284–9.
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366–74.
Nemec AA, Wallace SS, Sweasy JB. Variant base excision repair proteins: contributors to genomic instability. Semin Cancer Biol 2010; 20: 320–8.
Hazra TK, Das A, Das S, et al. Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair (Amst) 2007; 6: 470–80.
Edwards SK, Ono T, Wang S, et al. In vitro fluorogenic real-time assay of the repair of oxidative DNA damage. Chembiochem 2015; 16: 1637–46.
Hanssen-Bauer A, Solvang-Garten K, Sundheim O, et al. XRCC1 coordinates disparate responses and multiprotein repair complexes depending on the nature and context of the DNA damage. Environ Mol Mutagen 2011; 52: 623–35.
Vadhanam MV, Thaiparambil J, Gairola CG, et al. Oxidative DNA adducts detected in vitro from redox activity of cigarette smoke constituents. Chem Res Toxicol 2012; 25: 2499–504.
Simonelli V, Camerini S, Mazzei F, et al. Genotype-phenotype analysis of S326C OGG1 polymorphism: a risk factor for oxidative pathologies. Free Radic Biol Med 2013; 63: 401–9.
Takanami T, Nakamura J, Kubota Y, et al. The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. Mutat Res 2005; 582: 135–45.
Vodicka P, Stetina R, Polakova V, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 2007; 28: 657–64.
Slyskova J, Langie SA, Collins AR, et al. Functional evaluation of DNA repair in human biopsies and their relation to other cellular biomarkers. Front Genet 2014; 5: 116.
Markkanen E, Fischer R, Ledentcova M, et al. Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. Nucleic Acids Res 2015; 43: 3667–79.
Sacerdote C, Guarrera S, Ricceri F, et al. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer 2013; 133: 2004–9.
Patrono C, Sterpone S, Testa A, et al. Polymorphisms in base excision repair genes: breast cancer risk and individual radiosensitivity. World J Clin Oncol 2014; 5: 874–82.
van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004; 64: 1911–4.
Smal MP, Rolevich AI, Polyakov SL, et al. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients. Exp Oncol 2014; 36: 246–51.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315–22.
Ryk C, Kumar R, Sanyal S, et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006; 241: 142–9.
Gao W, Romkes M, Zhong S, et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep 2010; 24: 257–62.
Cho S, Kim MJ, Choi YY, et al. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer. Lung Cancer 2011; 73: 25–31.
Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997–1008.
Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815–25.
Ramaniuk VP, Nikitchenko NV, Savina NV, et al. Polymorphism of DNA repair genes OGG1, XRCC1, XPD, and ERCC6 in bladder cancer in Belarus. Biomarkers 2014; 19: 509–16.
Savina NV, Nikitchenko NV, Kuzhir TD, et al. The cellular response to oxidatively induced DNA damage and polymorphism of some DNA repair genes associated with clinicopathological features of bladder cancer. Oxid Med Cell Longev 2016; 2016: 5710403.
Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5: e13821.
Kim EJ, Kim YJ, Jeong P, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol 2008; 180: 1141–5.
Zöchbauer-Müller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249–55.
Sadikovic B, Al-Romaih K, Squire JA, et al. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008; 9: 394–408.
Kang Z, Li Y, Yu Y, et al. Research progress on bladder cancer molecular genetics. J Cancer Res Ther 2014; 10 Suppl: 89–94.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015; 15: 25–41.
Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148–59.
Smal MP, Rolevich AI, Nabebina TI, et al. Methylation of the RUNX3 gene as a prognosis factor in non-muscle invasive bladder cancer. Proc Nal Acad Sci Belarus 2015; 59: 85–90.
Smal MP, Rolevich AI, Nabebina TI, et al. The opposite association of HRAS and KRAS mutations with clinical variables of bladder cancer. Russian J of Genetics: Appl Res 2016; 6: 613–21.
Smal MP, Nikitchenko NV, Rolevich AI, et al. Influence of p16 gene methylation on the risk of progression of non-muscle invasive bladder cancer. Proc Nal Acad Sci Belarus 2018; 62: 322–8.
Kitchen MO, Bryan RT, Haworth KE, et al. Methylation of HOXA9 and ISL1 predicts patient outcome in high-grade non-invasive bladder cancer. PLoS One 2015; 10: e0137003.
García-Baquero R, Puerta P, Beltran M, et al. Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. Tumor Biol 2014; 35: 5777–86.
Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005; 41: 2769–78.
López-Knowles E, Hernández S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 7401–4.
Dueñas M, Martínez-Fernández M, García-Escudero R, et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog 2015; 54: 566–76.
Curtin K, Samowitz WS, Wolff RK, et al. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 3384–8.
Wan PT, Garnett MJ, Roe SM, et al. Cancer genome project: mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855–67.
McDaniel AS, Zhai Y, Cho K, et al. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol 2014; 45: 1957–65.
Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol 2009; 22: 627–32.
Kim YJ, Yoon HY, Kim JS, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer 2013; 133: 1135–42.
Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 2013; 10: 327–35.
Zhou X, Zhuang Z, Wang W, et al. OGG1 is essential in oxidative stress induced DNA demethylation. Cell Signal 2016; 28: 1163–71.
Bayraktar G, Kreutz MR. The role of activity-dependent DNA demethylation in the adult brain and in neurological disorders. Front Mol Neurosci 2018; 11: 169.
Martínez-Macías MI, Córdoba-Cañero D, Ariza RR, et al. The DNA repair protein XRCC1 functions in the plant DNA demethylation pathway by stimulating cytosine methylation (5-meC) excision, gap tailoring, and DNA ligation. J Biol Chem 2013; 288: 5496–505.
Hajkova P, Jeffries SJ, Lee C, et al. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science 2010; 329: 78–82.
Ploussard G, Dubosq F, Soliman H, et al. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology 2010; 76: 513.e13–8.
Igci M, Arslan A, Erturhan S, et al. Loss of heterozygosity of chromosome 13q33-34 region and molecular analysis of ING1 and p53 genes in bladder carcinoma. Mol Biol Rep 2015; 42: 507–16.
Hagiwara A, Kitajima Y, Sato S, et al. Allelic loss of the DNA repair gene OGG1 against oxidative damage in esophageal squamous cell carcinoma. Oncol Rep 2005; 13: 1009–16.
Arcand SL, Provencher D, Mes-Masson AM, Tonin PN. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol 2005; 27: 1315–20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
